1. Home
  2. APVO vs SNTG Comparison

APVO vs SNTG Comparison

Compare APVO & SNTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APVO
  • SNTG
  • Stock Information
  • Founded
  • APVO 2016
  • SNTG 2009
  • Country
  • APVO United States
  • SNTG China
  • Employees
  • APVO N/A
  • SNTG N/A
  • Industry
  • APVO Biotechnology: Pharmaceutical Preparations
  • SNTG Finance: Consumer Services
  • Sector
  • APVO Health Care
  • SNTG Finance
  • Exchange
  • APVO Nasdaq
  • SNTG Nasdaq
  • Market Cap
  • APVO 4.1M
  • SNTG 4.8M
  • IPO Year
  • APVO N/A
  • SNTG 2021
  • Fundamental
  • Price
  • APVO $3.23
  • SNTG $1.84
  • Analyst Decision
  • APVO Strong Buy
  • SNTG
  • Analyst Count
  • APVO 1
  • SNTG 0
  • Target Price
  • APVO $5,920.00
  • SNTG N/A
  • AVG Volume (30 Days)
  • APVO 6.6M
  • SNTG 6.5K
  • Earning Date
  • APVO 08-07-2025
  • SNTG 07-07-2025
  • Dividend Yield
  • APVO N/A
  • SNTG N/A
  • EPS Growth
  • APVO N/A
  • SNTG N/A
  • EPS
  • APVO N/A
  • SNTG N/A
  • Revenue
  • APVO N/A
  • SNTG $107,507.00
  • Revenue This Year
  • APVO N/A
  • SNTG N/A
  • Revenue Next Year
  • APVO N/A
  • SNTG N/A
  • P/E Ratio
  • APVO N/A
  • SNTG N/A
  • Revenue Growth
  • APVO N/A
  • SNTG N/A
  • 52 Week Low
  • APVO $2.81
  • SNTG $1.43
  • 52 Week High
  • APVO $485.37
  • SNTG $3.97
  • Technical
  • Relative Strength Index (RSI)
  • APVO 34.28
  • SNTG 54.53
  • Support Level
  • APVO $2.81
  • SNTG $1.67
  • Resistance Level
  • APVO $13.11
  • SNTG $1.92
  • Average True Range (ATR)
  • APVO 1.10
  • SNTG 0.09
  • MACD
  • APVO 0.30
  • SNTG 0.01
  • Stochastic Oscillator
  • APVO 4.08
  • SNTG 62.96

About APVO Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

About SNTG Sentage Holdings Inc.

Sentage Holdings Inc is a financial service provider that offers a comprehensive range of financial services across consumer loan repayment and collection management, loan recommendation, and prepaid payment network services in China.

Share on Social Networks: